<DOC>
	<DOCNO>NCT01056601</DOCNO>
	<brief_summary>Cancer result multiple mutation cause cell grow uncontrolled . It therefore may necessary inhibit several oncogenic target affect cancer cell growth . Studies show panobinostat ( LH589 ) cause wide range effect endothelial cell lead inhibition tumor angiogenesis ( fundamental step transition tumor dormant state malignant one ) . Bortezomib trigger cell death pancreatic cancer cell mechanism well define determine cytostatic . Combining two drug may work together treatment pancreatic cancer .</brief_summary>
	<brief_title>Panobinostat &amp; Bortezomib Pancreatic Cancer Progressing Gemcitabine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histological diagnosis locally advance metastatic pancreatic cancer ( except neuroendocrine tumor , include ampullary cancer ) progression standard first line therapy include gemcitabine ( single agent combination ) Measurable disease computated tomography ( CT ) scan per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion At least 28 day previous systemic therapy , include investigational agent 1st dose study treatment recover acute toxic effect treatment study enrollment . Has Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Ability provide write consent Must meet hematology biochemistry laboratory criterion within 14 day study enrollment : Neutrophil count &gt; 1500/mm^3 Platelet count &gt; 100,000/mm^L Hemoglobin &gt; = 9 g/dL Aspartate aminotransferase ( AST/SGOT ) Alanine transaminase ( ALT/SGPT ) &lt; = 2.5 time upper limit normal ( ULN ) ≤ 5.0 x ULN transaminase elevation due disease involvement Serum bilirubin &lt; = 1.5 x ULN Serum creatinine &lt; = 1.5 x ULN 24hour creatinine clearance ≥ 50 ml/min Total serum calcium ( correct serum albumin ) ionize calcium ≥ low limit normal ( LLN ) Serum phosphorus &gt; = LLN Serum potassium &gt; = LLN Serum sodium ≥ LLN Serum magnesium ≥ LLN Serum albumin ≥ LLN 3g/dl Patients elevated Alkaline Phosphatase due bone metastasis enrol Baseline multi gate acquisition scan ( MUGA ) echocardiogram ( ECHO ) must demonstration leave ventricular ejection fraction ( LVEF ) &gt; = 50 % Normal thyroid function within normal limit . Note : Patients permit receive thyroid hormone supplement treat underlying hypothyroidism . Women childbearing potential ( WOCBP ) must negative pregnancy test within 7 day study treatment administration willing use 2 method contraception &gt; 1 prior systemic treatment regimen pancreatic cancer Prior histone deacetylase ( HDAC ) , deacetylase ( DAC ) , heat shock protein 90 ( HSP90 ) inhibitor valproic acid treatment cancer Anyone need valproic acid medical condition study 5 day prior panobinostat treatment Impaired cardiac function Complete leave bundle branch block use permanent cardiac pacemaker , congenital long QT syndrome , history presence ventricular tachyarrhythmias , clinically significant rest bradycardia ( &lt; 50 beat per minute ) , QTcF &gt; 450 msec screen ECG , right bundle branch block + leave anterior hemiblock ( bifascicular block ) Presence atrial fibrillation ( ventricular heart rate &gt; 100 bpm ) Previous history angina pectoris acute myocardial infarction ( MI ) within 6 month study enrollment Congestive heart failure ( New York Heart Association functional classification IIIIV ) baseline MUGA/Echo show LVEF &lt; 50 % Uncontrolled hypertension define hypertensive blood pressure SBP &gt; 140 DBP &gt; 90 , despite antihypertensive medication History deep vein thrombosis ( DVT ) , pulmonary embolus blood clot abnormality within 3 month study enrollment Ongoing need anticoagulation therapy except daily low dose aspirin ( ≤ 100 mg/day ) low molecular weight heparin Concomitant use drug risk cause torsades de pointes Anyone unresolved diarrhea &gt; = grade 2 time enrollment Impairment gastrointestinal function disease may significantly alter absorption panobinostat Grade 2 great peripheral neuropathy within 14 day enrollment Serious concomitant medical psychiatric disorder ( e.g. , active infection , uncontrolled diabetes ) Patients receive chemotherapy , investigational agent undergone major surgery &lt; 4 week prior start study drug Male patient whose sexual partner WOCBP use double method contraception study 3 month follow . Known positivity human immunodeficiency virus ( HIV ) hepatitis C Hypersensitivity bortezomib , boron mannitol History another primary malignancy within 5 year curatively treat CIS cervix , basal squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>insulinoma</keyword>
	<keyword>cancer pancreas</keyword>
	<keyword>neoplasm , pancreas</keyword>
	<keyword>alpha-cell tumor</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>beta-cell tumor</keyword>
	<keyword>somatostatinoma</keyword>
</DOC>